STOCK TITAN

BEAM insider sale: 25,000 shares via option exercise on 10/02/2025

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

An insider filing under Rule 144 discloses the proposed sale of 25,000 common shares of Beam Therapeutics (BEAM). The shares were acquired via a stock option exercise and paid in cash on 10/02/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC with an indicated aggregate market value of $615,667.50 and the issuer's shares outstanding listed as 100,557,094. The filing also reports a prior sale of 25,000 shares on 10/01/2025 that generated $612,655.00 in gross proceeds. The filer certifies they are not aware of undisclosed material adverse information about the issuer.

Positive

  • Transaction disclosed publicly under Rule 144 with broker identified
  • Securities acquired via stock option exercise and paid in cash on the same date

Negative

  • Insider sale of 25,000 shares on 10/02/2025 (aggregate value $615,667.50) which may increase share supply
  • Prior sale of 25,000 shares on 10/01/2025 with $612,655.00 gross proceeds

Insights

Insider sold 25,000 shares following an option exercise on 10/02/2025.

The filing shows the shares were acquired by stock option exercise and paid in cash the same day, indicating the sale results from option liquidity rather than an open-market purchase. The transaction is routed through Morgan Stanley Smith Barney LLC with an aggregate market value of $615,667.50.

The filing also lists a separate sale of 25,000 shares on 10/01/2025 with $612,655.00 gross proceeds, showing consecutive insider dispositions. The filer affirms no undisclosed material adverse information.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the BEAM insider file disclose?

The filing discloses a proposed sale of 25,000 common shares acquired by stock option exercise and paid in cash on 10/02/2025.

Through which broker will the BEAM shares be sold?

The sale is to be executed through Morgan Stanley Smith Barney LLC at 1 New York Plaza.

What is the aggregate market value of the shares to be sold?

The filing lists an aggregate market value of $615,667.50 for the 25,000 shares.

Were there any recent prior insider sales disclosed?

Yes. The filing reports a sale of 25,000 shares on 10/01/2025 with gross proceeds of $612,655.00.

How many shares outstanding does the filing list for the issuer?

The filing lists 100,557,094 shares outstanding for the issuer.
Beam Therapeutics Inc.

NASDAQ:BEAM

BEAM Rankings

BEAM Latest News

BEAM Latest SEC Filings

BEAM Stock Data

2.88B
100.19M
1.19%
105.17%
25.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE